BFM
VYGR icon

Boothbay Fund Management’s Voyager Therapeutics VYGR Stock Holding History

Boothbay Fund Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-249
Closed -$413K – 879
2017
Q4 		$413K Sell
249
-249
-50% -$4.27K 0.06% 324
2017
Q3 		$1.02M Buy
+498
New +$5.62K 0.17% 143

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Boothbay Fund Management's VYGR Position: Q4 2025 in Review

Boothbay Fund Management sold out of Voyager Therapeutics (VYGR) in Q4 2025, closing a stake of 12,144 shares — an estimated $56.7K sold.

Boothbay Fund Management first reported a position in VYGR in Q4 2022 and held it in 12 quarters. The position peaked at $700K in Q2 2023. 125 funds tracked by Wall St. Rank hold VYGR as of Q4 2025.

  • Boothbay Fund Management reported no remaining Voyager Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 12,144 Voyager Therapeutics shares in Q4 2025, an estimated $56.7K.
  • Boothbay Fund Management first reported a position in Voyager Therapeutics in Q4 2022 and held it in 12 quarters.
  • Boothbay Fund Management's Voyager Therapeutics position peaked at $700K in Q2 2023.
  • 125 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.